Dietary Supplements

2025 data highlights widespread consumer use and value in supplements and clear support for modernizing the regulations overseeing the category.

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) today announced the appointment of M. Scott Furness, Ph.D., to serve as its new Senior Vice President of Regulatory & Scientific Affairs. Dr. Furness comes to CHPA from the U.S. Food and Drug Administration (FDA) where he spent more than 25 years in various leadership roles, most recently as Director of the Division of Product Quality Assessment XVIII at the Center for Drug Evaluation and Research’s (CDER) Office of Pharmaceutical Quality (OPQ), overseeing the scientific review and quality evaluation of the active pharmaceutical ingredient (API) section of regulatory applications and providing strategic guidance on pharmaceutical quality issues. Dr. Furness takes the role previously held by Mike Bailey and officially began his work at CHPA on May 6, 2025. He will serve as a member of CHPA’s Senior Management Team and report to President and CEO Scott Melville.

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) released the following statement today after submitting comments to the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) regarding its Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients:

CHPA believes FDA should continuously evaluate food colors for safety using a transparent science-based approach. Policy changes should be science based and realistic about implementation timelines and the complex manufacturing realities involved.